Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well gefitinib works in treating patients with
progressive metastatic neuroendocrine tumors. Gefitinib may stop the growth of tumor cells by
blocking the enzymes necessary for their growth.